Core Insights - Telix Pharmaceuticals reported a significant increase in Q3 2025 revenue, reaching approximately $206 million, which is a 53% increase year-over-year [3][6] - The company has raised its full-year 2025 revenue guidance to between $800 million and $820 million, reflecting strong performance in its PSMA imaging products [6][16] - Gozellix has received full reimbursement from the Centers for Medicare and Medicaid Services (CMS) in the U.S., effective October 1, 2025, enhancing its market position [6][15] Financial Performance - Q3 2025 group revenue was $206 million, compared to $135 million in Q3 2024, marking a 53% increase [3] - PSMA imaging revenue for Q3 2025 was $155 million, up 17% from $132 million in Q3 2024 [3] - RLS third-party revenue reached $47 million, with a notable increase from zero in Q3 2024 [3] Business Highlights - The company has two FDA-approved PSMA imaging agents, which are expected to enhance market share across various customer segments [4] - Gozellix's reimbursement status is expected to improve production flexibility and customer choice [4] - Telix has commenced commercial launches of Illuccix in multiple European markets, including the UK, Germany, and France [6][15] Clinical Development - The first patients have been dosed in the BiPASS™ trial, which aims to evaluate MRI combined with PSMA-PET imaging for prostate cancer diagnosis [6][15] - The ProstACT Global Phase 3 trial has opened for enrollment in several countries, including Australia, New Zealand, and Canada [7] - TLX250 has received ethics approval to commence a pivotal trial in advanced metastatic clear cell renal cell carcinoma [7] Regulatory and Corporate Updates - Telix has received radiation licenses for its manufacturing facilities in North Melbourne and Yokohama, preparing for operational readiness [12] - The company successfully executed a buy-out of remaining variable payments related to the acquisition of Advanced Nuclear Medicine Ingredients (ANMI) due to strong sales performance [13] - Telix plans to resubmit the New Drug Application for its brain cancer imaging candidate, Pixclara, during Q4 2025 [10]
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded